Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists

被引:24
作者
Inoue, Kazumi [1 ]
Urushibara, Ko [1 ]
Kanai, Misae [1 ]
Yura, Kei [2 ,3 ]
Fujii, Shinya [4 ,5 ]
Ishigami-Yuasa, Mari [4 ]
Hashimoto, Yuichi [5 ]
Mori, Shuichi [4 ]
Kawachi, Emiko [4 ]
Matsumura, Mio [1 ]
Hirano, Tomoya [4 ]
Kagechika, Hiroyuki [4 ]
Tanatani, Aya [1 ]
机构
[1] Ochanomizu Univ, Dept Chem, Fac Sci, Bunkyo Ku, Tokyo 1128610, Japan
[2] Ochanomizu Univ, Ctr Informat Biol, Bunkyo Ku, Tokyo 1128610, Japan
[3] Natl Inst Genet, Mishima, Shizuoka 4118540, Japan
[4] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan
[5] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan
关键词
Androgen receptor; Antagonist; Phthalazinone; Prostate cancer; TUMOR LNCAP CELLS; STRUCTURAL BASIS; PROSTATE-CANCER; MUTATION;
D O I
10.1016/j.ejmech.2015.08.002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 mu M) and showed high wt AR-binding affinity (IC50: 10.9 mu M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:310 / 319
页数:10
相关论文
共 32 条
  • [1] Drug therapy - Androgens in men - Uses and abuses
    Bagatell, CJ
    Bremner, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) : 707 - 714
  • [2] How Community Has Shaped the Protein Data Bank
    Berman, Helen M.
    Kleywegt, Gerard J.
    Nakamura, Haruki
    Markley, John L.
    [J]. STRUCTURE, 2013, 21 (09) : 1485 - 1491
  • [3] Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists
    Biswas, Kaustav
    Peterkin, Tanya A. N.
    Bryan, Marian C.
    Arik, Leyla
    Lehto, Sonya G.
    Sun, Hong
    Hsieh, Feng-Yin
    Xu, Cen
    Fremeau, Robert T.
    Allen, Jennifer R.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (20) : 7232 - 7246
  • [4] Structural basis for antagonism and resistance of bicalutamide in prostate cancer
    Bohl, CE
    Gao, WQ
    Miller, DD
    Bell, CE
    Dalton, JT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (17) : 6201 - 6206
  • [5] Targeting the androgen receptor pathway in prostate cancer
    Chen, Yu
    Sawyers, Charles L.
    Scher, Howard I.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) : 440 - 448
  • [6] ISOQUINO[3,2-A]PHTHALAZINE-5,8-DIONES
    DUSEMUND, J
    [J]. ARCHIV DER PHARMAZIE, 1982, 315 (11) : 925 - 930
  • [7] THE STEROID AND THYROID-HORMONE RECEPTOR SUPERFAMILY
    EVANS, RM
    [J]. SCIENCE, 1988, 240 (4854) : 889 - 895
  • [8] Chemistry and structural biology of androgen receptor
    Gao, WQ
    Bohl, CE
    Dalton, JT
    [J]. CHEMICAL REVIEWS, 2005, 105 (09) : 3352 - 3370
  • [9] PREPARATION OF A SUBSTITUTED 1,2-BENZOFLUORENONE - AN UNUSUAL PERKIN REACTION
    GODFREY, JC
    BARNES, RA
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1958, 80 (15) : 3902 - 3904
  • [10] Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance
    He, B
    Gampe, RT
    Kole, AJ
    Hnat, AT
    Stanley, TB
    An, G
    Stewart, EL
    Kalman, RI
    Minges, JT
    Wilson, EM
    [J]. MOLECULAR CELL, 2004, 16 (03) : 425 - 438